Taysha Gene Therapies, Inc. (TSHA) Net margin 2022–2025
Taysha Gene Therapies, Inc. (TSHA) net profit margin by fiscal year — reported net income divided by reported revenue.
-1115.3%FY2025 · since FY2022: -6635.3% → -1115.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -1115.3% | -43.6 pp |
| FY2024 | -1071.6% | -349.6 pp |
| FY2023 | -722.1% | +5913.2 pp |
| FY2022 | -6635.3% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More TSHA financial trends
TSHA RevenueTSHA Net incomeTSHA Gross profitTSHA Gross marginTSHA Operating incomeTSHA Operating marginTSHA Operating cash flowTSHA Free cash flowTSHA Capital expendituresTSHA Return on equityTSHA Stock buybacksTSHA Dividends paidTSHA Total assetsTSHA Total liabilitiesTSHA Shareholders’ equityTSHA overview →